Latest news

At Adalvo we are driven by our commitment to our partner network, dedicated to making a meaningful impact and improving patient lives globally. We are proud to share that Adalvo has been...

Adalvo has submitted its DCP filing for Teduglutide on Day-1 following the expiry of Data Exclusivity. Teduglutide has been developed for the treatment of short bowel syndrome (SBS), a rare condition...

Adalvo has recently signed a licensing and supply agreement with Dr. Reddy’s Laboratories to commercialise Dalbavancin Ready-to-Dilute (RTD) in the United States. Under this strategic agreement, Adalvo will license the exclusive...

Adalvo announces the successful DCP approval for Ethinylestradiol/Drospirenone 0.03mg /3mg tablets.  Based on the reference brand Yasmin, Ethinylestradiol/Drospirenone has been developed in collaboration with one of our strategic partners. The INN is a...

Adalvo has successfully launched Dimethyl Fumarate (DMF) across various markets, serving over 20 partners on three continents. Dimethyl Fumarate 120mg and 240mg hard capsules have been developed based on the reference brand Tecfidera,...

Adalvo has successfully launched the first and only Pregabalin Extended-Release (ER) tablets in Europe. This differentiated product has been introduced in two major European markets, Germany and Spain, through partnerships...

Adalvo secures successful DCP approval for Mirabegron 50mg prolonged-release tablets.  Developed based on the reference brand Betmiga prolonged-release tablets, Mirabegron is indicated for the treatment of urgency, increased micturition frequency, and/or...

Adalvo successfully launched the first and only Desmopressin Orally Disintegrating Tablets (ODT) in Europe in March 2024.  Developed based on the reference brand Minirin Melt, Desmopressin ODT is indicated for the...

Adalvo announces the successful earlier-than-expected DCP approval for Empagliflozin 10mg and 25mg film-coated tablets.  Our product has been developed based on the reference brand Jardiance film-coated tablets, which are indicated for...

Adalvo announces the restart of the DCP procedure for Dapagliflozin Film-Coated Tablets, with an anticipated EU Marketing Authorisation approval date in October 2024.  Developed based on the reference brand Forxiga film-coated...

Adalvo announces the successful DCP submission for Empagliflozin/Metformin film-coated tablets, with an anticipated approval date in June 2025.  Developed based on the reference brand Synjardy film-coated tablets, Empagliflozin/Metformin is indicated for...

Adalvo announces the successful DCP approval for Apixaban Tablets.   Based on the reference brand Eliquis, Apixaban is indicated for the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)....

Adalvo announces the addition of Voclosporin 7.9mg Soft Gel Capsules to its portfolio. Based on the reference brand Lupkynis, Voclosporin is indicated for treating adult patients with Lupus Nephritis (LN). Voclosporin represents the...

Adalvo announces the successful completion of the Pivotal BE study for Azacitidine 300mg film-coated tablets in adult patients with acute myeloid leukaemia (AML). Following the successful EU Pivotal BE study, Azacitidine...

As Deniz Kayadelen, Adalvo’s Brand Ambassador, prepares for her upcoming swim across the Catalina Channel on July 21st, we are reminded of the immense mental and physical challenges she faces....

Adalvo advances in the development of Fidaxomicin Film Coated Tablets 200mg, expecting dossier completion within the next six months. Following this, Adalvo intends to immediately file Fidaxomicin, having DCP slots already secured for...

Adalvo announces the addition of Olaparib Film Coated Tablets to its expanding oncology portfolio.  As a leading PARP inhibitor, Olaparib has received the most FDA approvals across four tumor types, underscoring...

Adalvo announces the successful launch of Rivaroxaban Film-Coated Tablets in the United Kingdom. Developed based on the reference brand Xarelto, Rivaroxaban is indicated for the prevention of atherothrombotic events in adult...